Characterization of a Ruthenium(III)/NAMI‐A Adduct with Bovine Serum Albumin that Exhibits a High Anti‐Metastatic Activity

An exchange for the better: X-ray absorption spectroscopic studies show that treatment of an RuIII drug, NAMI-A, with bovine serum albumin (BSA) results in complete replacement of the Cl− and S-donor ligands with N-donor and carboxylato residues of the protein (see scheme). The RuIII–BSA adduct is as active in enhancing the cell–substrate interactions as the original NAMI-A complex (which converts into RuIII–BSA within minutes in the cell-culture medium).